To include your compound in the COVID-19 Resource Center, submit it here.

GSK pruning pipeline, returning sirukumab rights to J&J

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) plans to discontinue more than 30 programs as it realigns its priorities to focus on a handful of therapeutic areas. The

Read the full 250 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE